• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

房颤导管消融患者围手术期持续华法林治疗策略的安全性与便利性

Safety and convenience of continuous warfarin strategy during the periprocedural period in patients who underwent catheter ablation of atrial fibrillation.

作者信息

Kwak Jae-Jin, Pak Hui-Nam, Jang Jin-Kun, Kim Sook Kyoung, Park Jae Hyung, Choi Jong-Il, Hwang Chun, Kim Young-Hoon

机构信息

Division of Cardiology, Yonsei University Health System, Seoul, Republic of Korea.

出版信息

J Cardiovasc Electrophysiol. 2010 Jun 1;21(6):620-5. doi: 10.1111/j.1540-8167.2009.01670.x. Epub 2009 Dec 21.

DOI:10.1111/j.1540-8167.2009.01670.x
PMID:20039992
Abstract

BACKGROUND

We investigated the efficiency and convenience of a continuous warfarinization (CW) strategy during the periprocedural period of radiofrequency catheter ablation (RFCA) of atrial fibrillation (AF) in comparison with the classic strategy of switching to heparin (SH).

METHODS AND RESULTS

We compared CW (n = 49) and SH (n = 55, 3 days before RFCA) in 104 patients who underwent RFCA of AF (77 males, 55 +/- 12 years old, paroxysmal AF: persistent AF = 63:41). During the procedure, the activated clotting time (ACT) was maintained between 350 and 400 seconds, and a requirement of H, postablation INR, and periprocedural complications were compared. Results were as follows: (1) in the CW group, the preprocedural INR (1.85 +/- 0.61 vs 1.05 +/- 0.12, P < 0.001) and the proportions of INR > 2.0 after RFCA (1st postprocedure day 61.2% vs 5.5%, P < 0.001; 2nd postprocedure day 83.3% vs 21.8%, P < 0.005) were higher, and the heparin requirement was lower (2012 +/- 998 U/30 minutes vs 2921 +/- 795 U/30 minutes, P < 0.001) than in the SH group. (2) The incidences of hemorrhagic complications (18.2% vs 18.4%, P = NS) or the major bleeding rates (reduced hemoglobin >or= 4 g/dL, requiring blood transfusion; 3.6% vs 12.2%, P = NS) were not significantly different in the CW group than in the SH group.

CONCLUSION

The periprocedural CW strategy maintains a more stable INR immediately after AF ablation without increasing hemorrhagic complications compared with the classic strategy of SH. Simple CW can replace SH in an experienced laboratory with a low risk of hemopericardium during AF ablation.

摘要

背景

我们研究了在心房颤动(AF)射频导管消融(RFCA)围手术期持续华法林化(CW)策略相较于转为使用肝素(SH)的经典策略的效率和便利性。

方法与结果

我们比较了104例行AF射频消融术患者(77例男性,55±12岁,阵发性AF:持续性AF = 63:41)中的CW组(n = 49)和SH组(n = 55,RFCA前3天)。术中,活化凝血时间(ACT)维持在350至400秒之间,并比较H的需求、消融后国际标准化比值(INR)和围手术期并发症。结果如下:(1)CW组术前INR(1.85±0.61 vs 1.05±0.12,P < 0.001)以及RFCA后INR>2.0的比例(术后第1天61.2% vs 5.5%,P < 0.001;术后第2天83.3% vs 21.8%,P < 0.005)更高,且肝素需求量低于SH组(2012±998 U/30分钟 vs 2921±795 U/30分钟,P < 0.001)。(2)CW组出血并发症发生率(18.2% vs 18.4%,P = NS)或严重出血率(血红蛋白降低≥4 g/dL,需要输血;3.6% vs 12.2%,P = NS)与SH组相比无显著差异。

结论

与SH经典策略相比,围手术期CW策略在AF消融术后能立即维持更稳定的INR,且不增加出血并发症。在有经验的实验室且AF消融期间心包积血风险较低时,简单的CW可替代SH。

相似文献

1
Safety and convenience of continuous warfarin strategy during the periprocedural period in patients who underwent catheter ablation of atrial fibrillation.房颤导管消融患者围手术期持续华法林治疗策略的安全性与便利性
J Cardiovasc Electrophysiol. 2010 Jun 1;21(6):620-5. doi: 10.1111/j.1540-8167.2009.01670.x. Epub 2009 Dec 21.
2
Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio.经导管消融治疗心房颤动患者的围手术期卒中及大出血并发症的管理:围手术期治疗国际标准化比值的影响。
Circulation. 2010 Jun 15;121(23):2550-6. doi: 10.1161/CIRCULATIONAHA.109.921320. Epub 2010 Jun 1.
3
Periprocedural anticoagulation for atrial fibrillation ablation.心房颤动消融术的围手术期抗凝治疗
J Cardiovasc Electrophysiol. 2008 Apr;19(4):362-6. doi: 10.1111/j.1540-8167.2007.01071.x. Epub 2008 Feb 12.
4
Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial.不同抗凝管理的房颤导管消融患者围术期卒中与出血并发症:来自华法林在房颤(AF)患者导管消融中预防血栓栓塞(COMPARE)随机试验的作用(Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation,COMPARE)的研究结果。
Circulation. 2014 Jun 24;129(25):2638-44. doi: 10.1161/CIRCULATIONAHA.113.006426. Epub 2014 Apr 17.
5
Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen.低分子量肝素在华法林中断期间作为桥接抗凝治疗:一种标准化围手术期抗凝方案的评估
Arch Intern Med. 2004 Jun 28;164(12):1319-26. doi: 10.1001/archinte.164.12.1319.
6
The optimal range of international normalized ratio for radiofrequency catheter ablation of atrial fibrillation during therapeutic anticoagulation with warfarin.华法林抗凝治疗期间行射频导管消融治疗心房颤动的国际标准化比值的最佳范围。
Circ Arrhythm Electrophysiol. 2013 Apr;6(2):302-9. doi: 10.1161/CIRCEP.112.000143. Epub 2013 Feb 26.
7
Warfarin is not needed in low-risk patients following atrial fibrillation ablation procedures.心房颤动消融术后的低风险患者无需使用华法林。
J Cardiovasc Electrophysiol. 2009 Sep;20(9):988-93. doi: 10.1111/j.1540-8167.2009.01481.x. Epub 2009 May 15.
8
Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.接受射频消融治疗心房颤动的患者中,不停用利伐沙班进行围手术期抗凝的可行性和安全性:多中心前瞻性注册研究结果。
J Am Coll Cardiol. 2014 Mar 18;63(10):982-8. doi: 10.1016/j.jacc.2013.11.039. Epub 2014 Jan 8.
9
Pulmonary vein antrum isolation for atrial fibrillation on therapeutic coumadin: special considerations.在服用华法林的情况下进行房颤的肺静脉电隔离:特殊考虑因素。
J Cardiovasc Electrophysiol. 2011 Feb;22(2):236-9. doi: 10.1111/j.1540-8167.2010.01940.x. Epub 2010 Nov 2.
10
Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation.治疗国际标准化比值对房颤消融期间激活凝血时间、肝素剂量和出血风险的影响。
J Cardiovasc Electrophysiol. 2011 Mar;22(3):248-54. doi: 10.1111/j.1540-8167.2010.01894.x. Epub 2010 Aug 31.

引用本文的文献

1
Prevention of venous thromboembolism in right heart-sided electrophysiological procedures: results of an European Heart Rhythm Association survey.右心 sided 电生理程序中预防静脉血栓栓塞症:一项欧洲心律协会调查的结果。
Europace. 2023 Dec 28;26(1). doi: 10.1093/europace/euad364.
2
Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias.心律失常成人患者行导管消融术时,中断与不中断抗凝治疗的比较。
Cochrane Database Syst Rev. 2021 Oct 21;10(10):CD013504. doi: 10.1002/14651858.CD013504.pub2.
3
Minimally Interrupted Non-Vitamin K Antagonist Oral Anticoagulants vs. Bridging Therapy and Uninterrupted Vitamin K Antagonists During Atrial Fibrillation Ablation: A Retrospective Single-Center Study.
心房颤动消融期间,最小中断非维生素K拮抗剂口服抗凝药与桥接治疗及持续维生素K拮抗剂的比较:一项回顾性单中心研究
Front Med (Lausanne). 2020 Jun 4;7:197. doi: 10.3389/fmed.2020.00197. eCollection 2020.
4
Uninterrupted anticoagulation with non-vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation: Lessons learned from randomized trials.心房颤动导管消融术中使用非维生素K拮抗剂口服抗凝剂进行不间断抗凝:随机试验的经验教训。
Clin Cardiol. 2019 Jan;42(1):198-205. doi: 10.1002/clc.23120. Epub 2018 Dec 7.
5
Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants.左心房消融术中的围手术期抗凝:间断和不间断使用维生素K拮抗剂或不间断使用新型抗凝剂。
BMC Cardiovasc Disord. 2018 Apr 27;18(1):71. doi: 10.1186/s12872-018-0804-6.
6
Metabolic benefits of rivaroxaban in non-valvular atrial fibrillation patients after radiofrequency catheter ablation.利伐沙班在射频导管消融术后非瓣膜性心房颤动患者中的代谢获益。
J Zhejiang Univ Sci B. 2017;18(11):946-954. doi: 10.1631/jzus.B1600492.
7
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.2017年心房颤动导管消融与外科消融治疗专家共识声明(由心律学会、欧洲心律协会、欧洲心血管病预防与康复协会、亚太心律学会、拉丁美洲心脏节律学会联合发布)
Europace. 2018 Jan 1;20(1):e1-e160. doi: 10.1093/europace/eux274.
8
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.2017年心房颤动导管消融与外科消融治疗专家共识声明:由心律学会(HRS)、欧洲心律协会(EHRA)、欧洲心血管病预防与康复协会(ECAS)、亚太心律学会(APHRS)及拉丁美洲心脏学会(SOLAECE)联合发布
Heart Rhythm. 2017 Oct;14(10):e275-e444. doi: 10.1016/j.hrthm.2017.05.012. Epub 2017 May 12.
9
Network meta-analysis of efficacy and safety of competitive oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation.竞争性口服抗凝剂在心房颤动射频导管消融患者中疗效和安全性的网状荟萃分析。
J Interv Card Electrophysiol. 2016 Sep;46(3):213-24. doi: 10.1007/s10840-016-0126-5. Epub 2016 Mar 21.
10
Early Experience of Novel Oral Anticoagulants in Catheter Ablation for Atrial Fibrillation: Efficacy and Safety Comparison to Warfarin.新型口服抗凝药用于心房颤动导管消融的早期经验:与华法林的疗效和安全性比较
Yonsei Med J. 2016 Mar;57(2):342-9. doi: 10.3349/ymj.2016.57.2.342.